Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

[1]  E. Wattel,et al.  Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. , 1998, Blood.

[2]  A. Reiter,et al.  Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages , 1998, British journal of haematology.

[3]  D. Blickstein,et al.  Thrombotic complications in essential thrombocythemia with relatively low platelet counts , 1997, American journal of hematology.

[4]  P. V. van Genderen,et al.  Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin , 1997, British journal of haematology.

[5]  A. Schafer,et al.  Microvascular Disturbances, Thrombosis, and Bleeding in Thrombocythemia: Current Concepts and Perspectives , 1997, Seminars in thrombosis and hemostasis.

[6]  R. Mesa,et al.  Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications , 1997, Seminars in thrombosis and hemostasis.

[7]  P. Koudstaal,et al.  Neurologic and Visual Symptoms in Essential Thrombocythemia: Efficacy of Low-Dose Aspirin , 1997, Seminars in thrombosis and hemostasis.

[8]  M. Bangerter,et al.  Aspirin in Essential Thrombocythemia: Status Quo and Quo Vadis , 1997, Seminars in thrombosis and hemostasis.

[9]  M. Griesshammer,et al.  Interferon-alpha in the treatment of essential thrombocythemia. , 1996, Leukemia & lymphoma.

[10]  T. Barbui,et al.  Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. , 1996, Leukemia & lymphoma.

[11]  S. Vukelja,et al.  Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea , 1996, American journal of hematology.

[12]  P. V. van Genderen,et al.  Hydroxyurea in essential thrombocytosis. , 1995, The New England journal of medicine.

[13]  A. Arboix,et al.  Ischemic stroke as first manifestation of essential thrombocythemia. Report of six cases. , 1995, Stroke.

[14]  T. Barbui,et al.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. , 1995, The New England journal of medicine.

[15]  H. Anderson,et al.  Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: Are safer drugs available? , 1995, European journal of haematology.

[16]  P. V. van Genderen,et al.  Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. , 1994, Presse medicale.

[17]  P. Koudstaal,et al.  Transient neurologic and ocular manifestations in primary thrombocythemia , 1993, Neurology.

[18]  N. Key,et al.  Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors , 1993, British journal of haematology.

[19]  F. Fabris,et al.  Sex and age as prognostic factors in essential thrombocythemia. , 1992, Haematologica.

[20]  M. N. Silverstein.  Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. , 1992, The American journal of medicine.

[21]  M. Colombi,et al.  Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients , 1991, Cancer.

[22]  E. Feliú,et al.  Life expectancy of patients with chronic nonleukemic myeloproliferative disorders , 1991, Cancer.

[23]  H. Hoagland,et al.  Essential thrombocythemia in young adults. , 1991, Mayo Clinic proceedings.

[24]  P. Fenaux,et al.  Clinical course of essential thrombocythemia in 147 cases , 1990, Cancer.

[25]  T. Barbui,et al.  Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. D'alessandro,et al.  Slowly progressive ischemic stroke as first manifestation of essential thrombocythemia. , 1989, Stroke.

[27]  R. Hehlmann,et al.  Essential thrombocythemia. Clinical characteristics and course of 61 cases , 1988, Cancer.

[28]  A. Vannucchi,et al.  Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients. , 1988, Clinical and laboratory haematology.

[29]  R. Berger,et al.  Essential thrombocythemias. Clinical evolutionary and biological data , 1986, Cancer.

[30]  J. Laszlo,et al.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.

[31]  J. Stuart,et al.  The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases , 1985, American journal of hematology.

[32]  E. Massey,et al.  Neurologic manifestations of essential thrombocythemia. , 1983, Annals of internal medicine.

[33]  R. Havlik,et al.  Uncontrolled thrombocytosis in chronic myeloproliferative disorders , 1982, British journal of haematology.

[34]  M. Pike,et al.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. , 1973, Biometrics.

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .